

Endo International plc Corporate Fact Sheet

Endo International plc is a highly focused generics and specialty branded pharmaceutical company delivering quality medicines through excellence in development, manufacturing and commercialization. Through our operating companies – Endo Pharmaceuticals, Par Pharmaceutical and Paladin Labs – Endo is dedicated to serving patients in need. Endo commenced operations in 1997 by acquiring certain pharmaceutical products, related rights and assets from The DuPont Merck Pharmaceutical Company. Since that time, the company has expanded to include the following business segments: U.S. Branded Pharmaceuticals, U.S. Generic Pharmaceuticals and International Pharmaceuticals.

Endo's strategy is to centralize and unify our business, driving productivity improvements. We will focus on organic growth by investing in hard-to-produce generic assets & technologies and transforming the branded business into a highly focused Specialty business. Additionally, we are concentrating on differentiated and intelligent product selection to shape our company for long-term success.

Endo has global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, Pennsylvania. We employ approximately 3,400 people worldwide.* For more information about Endo International and our operating companies, please visit www.endo.com.

*As of 10/31/2017

Our Operating Companies

Endo International plc

Business Segments		
U.S. Branded Pharmaceuticals	U.S. Generic Pharmaceuticals	International Pharmaceuticals
Operating Companies		
<p>Endo Pharmaceuticals</p> <p>Develops and markets high-value, quality branded pharmaceutical products to patients in need.</p>	<p>Par Pharmaceutical</p> <p>Develops, manufactures and markets safe, innovative and cost-effective generic pharmaceutical products that help improve patient quality of life.</p>	<p>Paladin Labs</p> <p>Providing innovative pharmaceutical products for the Canadian market.</p>

Our Global Presence



Our Vision for the Future

Our organization will continue to remain steadfast in our commitment to deliver pharmaceutical products of uncompromising quality and value with the highest levels of service. We will focus on smart product selection, operational execution and continuous improvement, consistently improving how we work, and how we develop and deliver the products we make. We will work as a unified company, creating a cohesive and efficient structure that supports both our Generics and Branded businesses. We will build out our portfolio and capabilities with a focus on core assets and businesses that are critical to our success.


At Endo, our high-performance organization has fostered an entrepreneurial culture that emphasizes integrity and compliance. Performance-Driven, Integrity, Quality & Continuous Improvement, Customer Focus and Collaboration are the Core Values that drive and inspire our employees and enable us to deliver superior service and products, as well as make a positive impact on our patients and customers.

Our Management Team

Paul V. Campanelli*	President, Chief Executive Officer and Director
Joseph A. Barbarite	Executive Vice President, Global Quality and Compliance
Patrick Barry	Senior Vice President, U.S. Branded Pharmaceuticals
Blaise Coleman*	Executive Vice President and Chief Financial Officer
Terrance J. Coughlin*	Executive Vice President and Chief Operating Officer
Larry Cunningham	Executive Vice President, Human Resources
Jennifer E. Dubas	Senior Vice President and Chief Compliance Officer
Rahul Garella	Senior Vice President, Head of International Pharmaceuticals
Matthew Maletta*	Executive Vice President, Chief Legal Officer
Stephen Mock	Senior Vice President, Investor Relations and Corporate Affairs
Tony Pera*	President, Par Pharmaceutical
Brandon Rockwell	Vice President, Business Development
Dan Rudio*	Senior Vice President, Controller and Chief Accounting Officer

*Section 16(b) Executive Officers

Our History



Our Corporate Information

Endo Global Headquarters
First Floor, Minerva House
Simmons Court Road
Ballsbridge
Dublin 4
Ireland
+353 1 268 2000

Endo U.S. Headquarters
1400 Atwater Drive
Malvern, PA 19355
484-216-0000
(800) 462-ENDO (3636)

NASDAQ Ticker Symbol: ENDP

Revised: November 2017

Investors/Media and Government Affairs
Stephen Mock
Senior Vice President, Investor Relations
and Corporate Affairs
845-364-4833
mock.stephen@endo.com

Media
Heather Zoumas-Lubeski
Senior Director, Corporate Affairs
484-216-6829
zoumaslubeski.heather@endo.com

Investors
Nina Goworek
Senior Director, Investor Relations
484-216-6657
goworek.nina@endo.com



© 2017 Endo Pharmaceuticals Inc. www.endo.com